Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3501]
News [8327]
Articles [66]
Editorials [9]
Conferences [224]
elearning [49]
ASCO 2013: Novel drug that inhibits Hsp90 effective as second-line therapy with docetaxel for advanced lung cancer
ASCO 2013: Novel drug that inhibits Hsp90 effective as second-line therapy with docetaxel for advanced lung cancer
ASCO 2013: Some patients with treatment-resistant colorectal cancers may have a new option
ASCO 2013: Some patients with treatment-resistant colorectal cancers may have a new option
ASCO 2013: Sorafenib stalls growth of treatment-resistant differentiated thyroid cancer
ASCO 2013: Sorafenib stalls growth of treatment-resistant differentiated thyroid cancer
ASCO 2013: Bevacizumab extends survival for relapsed and advanced cervical cancer
ASCO 2013: Bevacizumab extends survival for relapsed and advanced cervical cancer
ASCO 2013: Ten years of tamoxifen superior to five in reducing breast cancer recurrence and death
ASCO 2013: Ten years of tamoxifen superior to five in reducing breast cancer recurrence and death
ASCO 2013: Maintenance therapy with the multi-targeted drug pazopanib delays relapse of advanced ovarian cancer
ASCO 2013: Maintenance therapy with the multi-targeted drug pazopanib delays relapse of advanced ovarian cancer
ASCO completes electronic data sharing standard for breast cancer treatment
ASCO completes electronic data sharing standard for breast cancer treatment
ASCO 2013: Cetuximab superior to bevacizumab for advanced colorectal cancer
ASCO 2013: Cetuximab superior to bevacizumab for advanced colorectal cancer
ASCO 2013: New MEK inhibitor selumetinib is the first effective drug for advanced melanoma of the eye
ASCO 2013: New MEK inhibitor selumetinib is the first effective drug for advanced melanoma of the eye
ASCO 2013: Anti-PD-1 drug nivolumab shows high and durable clinical activity in patients with advanced melanoma
ASCO 2013: Anti-PD-1 drug nivolumab shows high and durable clinical activity in patients with advanced melanoma

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation